SEC Form 4 · accession 0001123292-16-001685

FIVE PRIME THERAPEUTICS INC · FPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Lewis T Williams

Officer — President and CEO · Director

Period of report

Feb 4, 2016

Accepted (ET)

Feb 8, 2016 · 5:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001175505

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 4, 2016	M	35,615	$4.56	A	375,967	D
Common Stock^F2	Feb 4, 2016	S	20,086	$32.79	D	355,881	D
Common Stock^F3	Feb 4, 2016	S	11,800	$33.83	D	344,081	D
Common Stock^F4	Feb 4, 2016	S	3,729	$34.84	D	340,352	D
Common Stock	Feb 4, 2016	M	35,614	$4.56	A	375,966	D
Common Stock^F5	Feb 4, 2016	S	18,557	$32.74	D	357,409	D
Common Stock^F6	Feb 4, 2016	S	12,408	$33.76	D	345,001	D
Common Stock^F7	Feb 4, 2016	S	4,528	$34.70	D	340,473	D
Common Stock^F8	Feb 4, 2016	S	121	$35.48	D	340,352	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F9	$4.56	Feb 4, 2016	M	35,615	D	—	Apr 15, 2019	Common Stock	35,615	126,986	D
Employee Stock Option (right to buy)^F9	$4.56	Feb 4, 2016	M	35,614	D	—	Apr 15, 2019	Common Stock	35,614	91,372	D

Explanation of responses

F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 4, 2015.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.43 to $33.41, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, 5, 6, 7 and 8 to this Form 4.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.43 to $34.42, inclusive.
F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.46 to $35.45, inclusive.
F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.36 to $33.35, inclusive.
F6The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.36 to $34.32, inclusive.
F7The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.36 to $35.33, inclusive.
F8The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.37 to $35.50, inclusive.
F9This option is fully vested and immediately exercisable.